These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 24580813)

  • 61. Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence.
    Blumenthal J; Haubrich R
    Expert Opin Pharmacother; 2013 Sep; 14(13):1777-85. PubMed ID: 23800167
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PrEP as Peri-conception HIV Prevention for Women and Men.
    Heffron R; Pintye J; Matthews LT; Weber S; Mugo N
    Curr HIV/AIDS Rep; 2016 Jun; 13(3):131-9. PubMed ID: 26993627
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
    Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
    PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
    Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
    JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Becoming adherent to a preventive treatment for HIV: a qualitative approach.
    Puppo C; Mabire X; Morel S; Laguette V; Rojas Castro D; Chas J; Cua E; Pintado C; Suzan-Monti M; Spire B; Molina JM; Préau M
    Psychol Health Med; 2020 Mar; 25(3):270-281. PubMed ID: 31294630
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis.
    Celum C; Baeten JM
    Antivir Ther; 2012; 17(8):1483-93. PubMed ID: 23221365
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review.
    Hankins CA; Dybul MR
    Curr Opin HIV AIDS; 2013 Jan; 8(1):50-8. PubMed ID: 23201856
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.
    Gengiah TN; Moosa A; Naidoo A; Mansoor LE
    Int J Clin Pharm; 2014 Feb; 36(1):70-85. PubMed ID: 24129582
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.
    Lykins WR; Luecke E; Johengen D; van der Straten A; Desai TA
    Drug Deliv Transl Res; 2017 Dec; 7(6):805-816. PubMed ID: 28612340
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
    Baeten JM; Grant R
    Curr HIV/AIDS Rep; 2013 Jun; 10(2):142-51. PubMed ID: 23494772
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis.
    Traeger MW; Schroeder SE; Wright EJ; Hellard ME; Cornelisse VJ; Doyle JS; Stoové MA
    Clin Infect Dis; 2018 Aug; 67(5):676-686. PubMed ID: 29509889
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study.
    Closson EF; Mitty JA; Malone J; Mayer KH; Mimiaga MJ
    AIDS Care; 2018 Feb; 30(2):191-198. PubMed ID: 28830220
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
    Liu AY; Cohen SE; Vittinghoff E; Anderson PL; Doblecki-Lewis S; Bacon O; Chege W; Postle BS; Matheson T; Amico KR; Liegler T; Rawlings MK; Trainor N; Blue RW; Estrada Y; Coleman ME; Cardenas G; Feaster DJ; Grant R; Philip SS; Elion R; Buchbinder S; Kolber MA
    JAMA Intern Med; 2016 Jan; 176(1):75-84. PubMed ID: 26571482
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Using Behavioral Economics to Support PrEP Adherence for HIV Prevention.
    Roy Paladhi U; Katz DA; Farquhar C; Thirumurthy H
    Curr HIV/AIDS Rep; 2022 Oct; 19(5):409-414. PubMed ID: 36044119
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low- and middle-income countries: a systematic review and meta-analysis.
    Yi S; Tuot S; Mwai GW; Ngin C; Chhim K; Pal K; Igbinedion E; Holland P; Choub SC; Mburu G
    J Int AIDS Soc; 2017 Jun; 20(1):21580. PubMed ID: 28691439
    [TBL] [Abstract][Full Text] [Related]  

  • 78. From modeling to morals: imagining the future of HIV PREP in Lesotho.
    Kenworthy NJ; Bulled N
    Dev World Bioeth; 2013 Aug; 13(2):70-8. PubMed ID: 23800326
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combining information to estimate adherence in studies of pre-exposure prophylaxis for HIV prevention: Application to HPTN 067.
    Hughes JP; Williamson BD; Krakauer C; Chau G; Ortiz B; Wakefield J; Hendrix C; Amico KR; Holtz TH; Bekker LG; Grant R
    Stat Med; 2022 Mar; 41(6):1120-1136. PubMed ID: 35080038
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach.
    Blashill AJ; Ehlinger PP; Mayer KH; Safren SA
    Clin Infect Dis; 2015 Jun; 60 Suppl 3(Suppl 3):S187-90. PubMed ID: 25972502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.